Comparison
3 Methylglutaconic Aciduria Type 2 C0574083 vs 3q13 Microdeletion Syndrome C2931338
Clinical comparison between 3 Methylglutaconic Aciduria Type 2 and 3q13 Microdeletion Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 2 C0574083
Also called Barth syndrome, this genetic condition primarily affects males and impairs mitochondrial function. It causes heart muscle weakness, muscle weakness, and recurrent infections. Treatment includes cardiac care, infection prevention, and supportive therapies.
3q13 Microdeletion Syndrome C2931338
A genetic disorder from missing material on chromosome 3q13, associated with developmental delays, intellectual disability, and various congenital features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 2 C0574083
0-5
3q13 Microdeletion Syndrome C2931338
Variable
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 2 C0574083
severe
3q13 Microdeletion Syndrome C2931338
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 2 C0574083
Chronic
3q13 Microdeletion Syndrome C2931338
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 2 C0574083
No
3q13 Microdeletion Syndrome C2931338
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3q13 Microdeletion Syndrome C2931338
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3q13 Microdeletion Syndrome C2931338
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-2-C0574083 and 3q13-microdeletion-syndrome-C2931338 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3q13 Microdeletion Syndrome C2931338 | Discriminating power |
|---|---|---|---|
| Heart involvement | Cardiomyopathy or heart-muscle weakness is a characteristic concern. | Not primarily defined by cardiomyopathy; congenital findings vary. | High |
| Infections | Recurrent infections may accompany neutropenia. | Infection susceptibility is not a defining feature in the supplied data. | High |
| Development | Muscle weakness and growth problems may occur; cognition is not the core descriptor. | Developmental delay and intellectual disability are central features. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 2 C0574083 when
Male infant or child with cardiomyopathy and muscle weakness
This pattern fits the described mitochondrial phenotype better than a chromosomal microdeletion.
Moderate
Recurrent infections with suspected neutropenia
Infection risk is specifically described for type 2, not 3q13 deletion.
Moderate
Abnormal urine organic-acid pattern plus compatible clinical findings
An abnormal metabolite result supports evaluation, but alone does not establish the diagnosis.
High
Choose 3q13 Microdeletion Syndrome C2931338 when
Developmental delay with congenital anomalies
This aligns with the described chromosomal phenotype rather than a primary metabolic cardiomyopathy.
Moderate
Confirmed missing material at chromosome 3q13
A validated chromosomal finding directly supports the microdeletion diagnosis after genetics review.
High
No characteristic cardiac, muscle, or infection pattern
Absence of the type 2 pattern makes the chromosomal condition more plausible, but does not exclude other disorders.
Low
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3q13 Microdeletion Syndrome C2931338 | Interpretation |
|---|---|---|---|
| Urine organic acids | 3-methylglutaconic acid elevation may be found. | No characteristic organic-acid abnormality is established. | An abnormal result is not itself a diagnosis and needs clinical and genetic correlation. |
| Blood count | Neutropenia may be present and can vary over time. | No characteristic blood-count abnormality is supplied. | Results should be interpreted with infection history; normal counts do not exclude either condition. |
| Chromosomal microarray | No 3q13 deletion is expected from the supplied description. | Deletion involving 3q13 supports the syndrome when clinically correlated. | Genetic results require specialist confirmation and family counseling. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 2 C0574083
- Outcome
- Chronic and potentially severe, especially through cardiac and infection-related complications.
- Factors
- Heart function, infection frequency, growth, and access to specialist care.
3q13 Microdeletion Syndrome C2931338
- Outcome
- Chronic with variable developmental impact; severe complications are not established here.
- Factors
- Deletion extent, developmental profile, congenital features, and support services.
Time frame: Often recognized in early childhood, with lifelong follow-up; onset of the deletion phenotype may vary.
Prognosis cannot be individualized from these descriptions alone.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiac complications | Heart-muscle weakness may lead to significant cardiac illness. Major cardiac disease is not established as characteristic. Cardiac surveillance is especially relevant for type 2; exact risk is not quantified here. |
| Infection | Recurrent infections are a recognized concern. No specific infection complication is established. Fever or suspected infection needs prompt clinical assessment, particularly in type 2. |
| Neurodevelopment | Muscle weakness may limit activity; cognitive outcome is not defined here. Developmental delay and intellectual disability may require long-term support. Needs vary widely and should be individualized. |
Patient education highlights
- HighUrgent symptoms
Seek urgent care for breathing difficulty, poor feeding, fainting, or suspected serious infection.
- HighDiagnosis limits
Laboratory or chromosomal abnormalities require specialist interpretation and do not replace a full diagnosis.
- MediumSupportive care
Cardiac care, infection prevention, developmental therapy, and educational support depend on the confirmed condition.